Literature DB >> 24077222

Prognosis of primary aldosteronism in Japan: results from a nationwide epidemiological study.

Yoshihiro Miyake1, Keiko Tanaka, Tetsuo Nishikawa, Mitsuhide Naruse, Ryoichi Takayanagi, Hironobu Sasano, Yoshiyu Takeda, Hirotaka Shibata, Masakatsu Sone, Fumitoshi Satoh, Masanobu Yamada, Hajime Ueshiba, Takuyuki Katabami, Yasumasa Iwasaki, Hirotoshi Tanaka, Yusuke Tanahashi, Shigeru Suzuki, Tomonobu Hasegawa, Noriyuki Katsumata, Toshihiro Tajima, Toshihiko Yanase.   

Abstract

The Research Committee of Disorders of Adrenal Hormones, Japan, undertook a nationwide epidemiological study of primary aldosteronism (PA). The present study was undertaken as a part of this study to reveal the relationship between type of treatment and the prognosis of PA. In the primary survey, 4161 patients with PA during the period January 1, 2003-December 31, 2007 were reported from 3252 departments of internal medicine, pediatrics and urology. In the secondary survey, a questionnaire that requested detailed clinical information on individual patients was sent to those departments reporting patients in the primary survey. In total, data on 1706 patients with PA were available in the present study. Among patients with bilateral or unilateral aldosterone-producing adenoma, after adjustment for age at which prognosis was examined, sex, surgical treatment and medical treatment, surgical treatment was significantly associated with amelioration of hypertension (adjusted odds ratio [OR]: 0.47 [95% confidence interval (CI): 0.29-0.77]) and hypokalemia (adjusted OR: 0.17 [95% CI: 0.11-0.29]). No significant relationship was observed between medical treatment and such prognosis in this group of patients. Among patients with bilateral or unilateral adrenal hyperplasia, surgical, but not medical, treatment was significantly associated with amelioration of hypokalemia (adjusted OR: 0.23 [95% CI: 0.06-0.74]), while there was no relationship between surgical or medical treatment and the prognosis of hypertension. In conclusion, surgery offered a better prognosis of PA than medication with regards to hypertension and hypokalemia, with the limitation that a new anti-aldosterone drug, eplerenone, was not available during the study period.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24077222     DOI: 10.1507/endocrj.ej13-0353

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  9 in total

Review 1.  Issues in the Diagnosis and Treatment of Primary Aldosteronism.

Authors:  Jacopo Burrello; Silvia Monticone; Fabrizio Buffolo; Martina Tetti; Giuseppe Giraudo; Domenica Schiavone; Franco Veglio; Paolo Mulatero
Journal:  High Blood Press Cardiovasc Prev       Date:  2015-04-09

Review 2.  Aldosterone excess and resistant hypertension: investigation and treatment.

Authors:  Michael Stowasser
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

3.  Complete remission of hypertension in a hemodialysis patient after adrenalectomy for primary aldosteronism and renal transplantation.

Authors:  Daisuke Watanabe; Satoshi Morimoto; Noriyoshi Takano; Shihori Kimura; Yasufumi Seki; Kanako Bokuda; Midori Sasaki-Yatabe; Junichi Yatabe; Hiromi Onizuka; Tomoko Yamamoto; Takashi Ando; Atsuhiro Ichihara
Journal:  CEN Case Rep       Date:  2017-12-29

4.  Effect of Treatment on Body Fluid in Patients with Unilateral Aldosterone Producing Adenoma: Adrenalectomy versus Spironolactone.

Authors:  Che-Hsiung Wu; Ya-Wen Yang; Szu-Chun Hung; Yao-Chou Tsai; Ya-Hui Hu; Yen-Hung Lin; Tzong-Shinn Chu; Kwan-Dun Wu; Vin-Cent Wu
Journal:  Sci Rep       Date:  2015-10-19       Impact factor: 4.379

5.  Long term outcome of Aldosteronism after target treatments.

Authors:  Vin-Cent Wu; Shuo-Meng Wang; Chia-Hui Chang; Ya-Hui Hu; Lian-Yu Lin; Yen-Hung Lin; Shih-Chieh Jeff Chueh; Likwang Chen; Kwan-Dun Wu
Journal:  Sci Rep       Date:  2016-09-02       Impact factor: 4.379

6.  Composite Cardiovascular Outcomes in Patients With Primary Aldosteronism Undergoing Medical Versus Surgical Treatment: A Meta-Analysis.

Authors:  Wei-Chieh Huang; Ying-Ying Chen; Yen-Hung Lin; Jeff S Chueh
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-17       Impact factor: 5.555

7.  A case of primary aldosteronism with a negative aldosterone-to-renin ratio.

Authors:  Fengyi Liu; Liang Wang; Yanchun Ding
Journal:  BMC Cardiovasc Disord       Date:  2021-07-22       Impact factor: 2.298

8.  Association of Papillary Thyroid Carcinoma with Primary Aldosteronism.

Authors:  Shigenori Nakamura; Masatoshi Ishimori; Noriyoshi Yamakita
Journal:  Intern Med       Date:  2018-10-17       Impact factor: 1.271

9.  Evaluation of various confirmatory tests for the diagnosis of aldosterone-producing adenoma.

Authors:  Satoshi Kidoguchi; Naoki Sugano; Ruri Kawauchi; Daisuke Nakashima; Naomi Hayashi-Ishikawa; Goro Tokudome; Takashi Yokoo
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2020 Apr-Jun       Impact factor: 1.636

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.